Diet and prostate cancer risk reduction

Expert Review of Anticancer Therapy

Volumn 8, Issue 1, 2008, Pages 43-50

  Cheung, Eric ^a   Wadhera, Panikar ^a   Dorff, Tanya ^a   Pinski, Jacek ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cancer; Diet; Green tea; Lycopene; Prostate; Risk; Selenium; Soy; Vitamin D; Vitamin E

Indexed keywords

ALPHA CAROTENE; ALPHA TOCOPHEROL; BETA CAROTENE; BETA CRYPTOXANTHIN; CAROTENOID; CATECHIN; DAIDZEIN; EPIGALLOCATECHIN GALLATE; EQUOL; GENISTEIN; GREEN TEA EXTRACT; ISOFLAVONE; LYCOPENE; PLACEBO; SELENIUM; SOYBEAN PROTEIN; VITAMIN D;

CANCER RISK; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIET SUPPLEMENTATION; DIETARY INTAKE; FRUIT; HUMAN; LUNG CANCER; MINERAL BLOOD LEVEL; MONOTHERAPY; NUTRITIONAL SUPPORT; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; RISK REDUCTION; SOYBEAN; TEA; TOMATO; TOXICITY TESTING; VEGETABLE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; ANIMAL; DIET; DIET THERAPY; MALE; PATHOLOGY; PROSTATE TUMOR;

ANIMALS; DIET; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 38349008675     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.1.43     Document Type: Review

References (73)

1. Jemal A, Siegel R, Ward E. Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. Cancer J. Clin. 57(1), 43-66 (2007).
2. Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in Adventist men. Cancer 64(1), 598-604 (1989).
3. Tzonou A, Signorello LB, Lagiou P, Wuu J, Trichopoulos D, Trichopoulou A. Diet and cancer of the prostate: a case-control study in Greece. Int. J. Cancer 80, 704-708 (1999).
4. Norrish AE, Jackson RT, Sharpe SJ, Skeaff CM. Prostate cancer and dietary carotenoids. Am. J. Epidemiol. 151, 119-123 (2000).
5. Giovannucci E, Rimm EB, Liu Y, Stampfer MJ, Willett WC. A prospective study of tomato products, lycopene, and prostate cancer risk. J. Natl. Cancer Inst. 94, 391-398 (2002).
6. Gann PH, Ma J, Giovannucci E et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 59, 1225-1230 (1999).
7. Lu QY, Hung JC, Heber D et al. Inverse associations between plasma lycopene and other carotenoids and prostate cancer. Cancer Epidemiol. Biomarkers Prev. 10, 749-756 (2001).
8. Vogt TM, Mayne ST, Graubard BI et al. Serum lycopene, other serum carotenoide, and risk of prostate cancer in US blacks and whites. Am. J. Epidemiol. 155(1), 1023-1032 (2002).
9. Wu K, Erdman JW Jr, Schwartz SJ et al. Plasma and dietary carotenoids, and the risk of prostate cancer: a nested case-control. Cancer Epidemiol. Biomarkers 13, 260-269 (2004).
10. Key TJ, Silcocks PB, Davey GK, Appleby PN, Bishop DT. A case-control study of diet and prostate cancer. Br. J. Cancer 76, 678-687 (1997).
11. Le Marchand L, Hankin JH, Kolonel LN, Wilkens LR. Vegetable and fruit consumption in relation to prostate cancer risk in Hawaii: a reevaluation of the effect of dietary β-carotene. Am. J. Epidemiol. 133, 215-219 (1991).
12. Hayes RB, Ziegler RG, Gridley G et al. Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol. Biomarkers Prev. 8, 25-34 (1999).
13. Kolonel LN, Hankin JH, Whittemore AS et al. Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. Cancer Epidemiol. Biomarkers Prev. 9, 795-804 (2000).
14. Schuurman AG, Goldbohm RA, Dorant E, van den Brandt PA. Vegetable and fruit consumption and prostate cancer risk: a cohort study in the Netherlands. Cancer Epidemiol. Biomarkers Prev. 7, 673-680 (1998).
15. Hsing AW, Comstock GW, Abbey H, Polk BF. Serologic precursors of cancer. Retinol, carotenoids, and tocopherol and risk of prostate cancer. J. Natl Cancer Inst. 82, 941-946 (1990).
16. Nomura AM, Stemmermann GN, Lee J, Craft NE. Serum micronutrients and prostate cancer in Japanese-Americans in Hawaii. Cancer Epidemiol. Biomarkers Prev. 6, 487-491 (1997).
17. Peters U, Leitzmann MF, Chatterjee N et al. Serum lyc̊opene other carotenoids, and prostate cancer risk: a nested case-control study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol. Biomarkers Prev. 16(5), 962-968 (2007).
18. Yoshizawa K, Willett WC, Morris SJ et al. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J. Natl Cancer Inst. 90, 1219-1224 (1998).
19. Helzlsouer KJ, Huang HY, Alberg AJ et al. Association between α-tocopherol, γtocopherol, selenium, and subsequent prostate cancer. J. Natl Cancer Inst. 92, 2018-2023 (2000).
20. Lipsky K, Ziguener MZ, Schips L, Plummer K, Rehak P, Humber G. Selenium levels of patients with newly diagnosed prostate cancer compared with control group. Urology 63, 912-916 (2004).
21. Ghadirian P, Maisonneuve P, Perret C, Kennedy G, Boyle P, Krewsi D. A case-control study of toenail selenium and cancer of the breast, colon and prostate. Cancer Detect. Prevent. 24, 305-313 (2000).
22. Allen NE, Morris JS, Ngwenyama RA et al. A case-control study of selenium in nails and prostate cancer risk in British men. Br. J. Cancer 90, 1392-1396 (2004).
23. Li H, Stampfer MJ, Giovannucci EL et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst. 96, 696-703 (2004).
24. Vogt TM, Ziegler RG, Patterson BH, Graubard BI. Racial differences in serum selenium concentration: analysis of US population data from the third national health and nutrition examination survey. Am. J. Epidemiol. 166(3), 280-288 (2007).
25. Peters U, Foster CB, Chatterjee N et al. Serum selenium and risk of prostate cancer - a nested case-control study. Am. J. Clin. Nutr. 85(1), 209-217 (2007).
26. Nomura AM, Lee J, Stemmermann GN et al. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 9, 883-887 (2000).
27. Hartman T, Albanes D, Pietinen P et al. The association between baseline vitamin E, selenium, and prostate cancer in the Alpha-Tocoperol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiol. Biomarkers Prev. 7, 335-340 (1998).
28. Goodman GE, Schaffer S, Bankson DD, Hughes MP, Omenn GS. Carotene and retinol efficacy trial co-investigators. Predictors of serum selenium in cigarette smokers and the lack of association with lung and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 10(10), 1069-1076 (2001).
29. Clark LC, Dalkin B, Krongrad A et al. Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. Br. J. Urol. 81(5); 730-734 (1998).
30. Duffield-Lillico AJ, Dalkin BL, Reid ME et al. Nutritional Prevention of Cancer Study group. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 91(7), 608-612 (2003).
31. Clark LC, Combs GF Jr, Turnbull BW et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 276, 1957 (1996).
32. Huttunen JK. Selenium and cardiovascular diseases - an update. Biomed. Environ. Sci. 10, 220 (1997).
33. Kadrabova J, Mad'aric A, Kovacikova Z et al. Selenium status is decreased in patients with intrinsic asthma. Biol. Trace Elem. Res. 52, 241 (1996).
34. Karaküçük S, Ertugrul Mirza G, Faruk Ekinciler O et al. Selenium concentrations in serum, lens and aqueous humour of patients with senile cataract. Acta Ophthalmol. Scand. 73, 329-332 (1995).
35. Yegin A, Yegin H, Aliciguzel Y et al. Erythrocyte selenium-glutathione peroxidase activity is lower in patients with coronary atherosclerosis. Jpn Heart J. 38, 793-798 (1997).
36. Lippman SM, Goodman PJ, Klein EA et al. Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J. Natl Cancer Inst. 97, 94-102 (2005).
37. Deneo-Pellegrini H, De Stefani E, Ronco A et al. Foods, nutrients and prostate cancer: a case-control study in Uruguay. Br. J. Cancer 80, 591-597 (1999).
38. Hartman TJ, Dorgan JF, Virtamo J, Tangrea JA, Taylor PR, Albanes D. Association between serum α-tocopherol and serum androgens and estrogens in older men. Nutr. Cancer 35(1), 10-15 (1999).
39. Eichholzer M, Stahelin HB, Gey KF et al. Prediction of male cancer mortality by plasma levels of interacting vitamins: 17-year follow-up of the prospective Basel study. Int. J. Cancer 66, 145-150 (1996).
40. Goodman GE, Schaffer S, Omenn GS et al. The association between lung and prostate cancer risk, and serum micronutrients: results and lessons learned from β-carotene and retinol efficacy trial. Cancer Epidemiol. Biomarkers Prev. 12, 518-526 (2003).
41. Heinoinen OP, Albanes D, Virtamo J et al. Prostate cancer and supplementation with αtocopherol and carotene: incidence and mortality in a controlled trial. J. Natl. Cancer Inst. 90, 440-446 (1998).
42. Weinstein SJ, Wright ME, Lawson KA et al. Serum and dietary vitamin E in relation to prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 16(6), 1253-1259 (2007).
43. Huang HY, Alberg AJ, Norkus EP et al. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am. J. Epidemiol. 157, 335-344 (2003).
44. Weinstein SJ, Wright ME, Pietinen P et al. Serum α-tocopherol and γ-tocopherol in relation to prostate cancer risk in a prospective study. J. Natl Cancer Inst. 97(5), 396-399 (2005).
45. Chan JM, Stampfer MJ, Ma J et al. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in the United States. Cancer Epidemiol. Biomarkers Prev. 8, 893-899 (1999).
46. Lonn E, Bosch J, Yusuf S et al. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293, 1338-1347 (2005).
47. Rodriguez C, Jacobs EJ, Mondul AM et al. Vitamin E supplements and risk of prostate cancer in U.S. men. Cancer Epidemiol. Biomarkers Prev. 13, 378-382 (2004).
48. Kirsh VA, Hayes RB, Mayne ST et al. Supplemental and dietary vitamin E, β-carotene, and vitamin C intakes and prostate cancer risk. J. Natl Cancer Inst. 98, 245-254 (2006).
49. Holzbeierlein JM, McIntosh J, Thrasher JB. The role of soy phytoestrogens in prostate cancer. Curr. Opin. Urol. 15(1), 17-22 (2005).
50. Nagata C, Inaba S, Kawakami N, Kakizoe T, Shimizu H. Inverse association of soy product intake with serum androgen and estrogen concentrations in Japanese men. Nutr. Cancer 36(1), 14-18 (2000).
51. Yan L, Spitznagel EL. Meta-analysis of soy food and risk of prostate cancer in men. Int. J. Cancer 117(4), 667-669 (2005).
52. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol. Biomarkers Prev. 12(7), 665-668 (2003).
53. Ozasa K, Nakao M, Watanabe Y et al. JACC Study Group. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci. 95(1), 65-71 (2004).
54. Kurahashi N, Iwasaki M, Sasazuki S, Otani T, Inoue M, Tsugane S. Japan Public Health Center-Based Prospective Study Group. Soy product and isoflavone consumption in relation to prostate cancer in Japanese men. Cancer Epidemiol. Biomarkers Prev. 16(3), 538-545 (2007).
55. Nagata Y, Sonoda T, Mori M et al. Dietary isoflavones may protect against prostate cancer in Japanese men. J. Nutr. 137(8), 1974-1979 (2007).
56. Heald CL, Ritchie MR, Bolton-Smith C, Morton MS, Alexander FE. Phyto-oestrogens and risk of prostate cancer in Scottish men. Br. J. Nutr. 98(2), 388-396 (2007).
57. Nomura AM, Hankin JH, Lee J, Stemmermann GN. Cohort study of tofu intake and prostate cancer: no apparent association. Cancer Epidemiol. Biomarkers Prev. 13(12), 2277-2279 (2004).
58. Alekel DL, St Germain A, Peterson CT et al. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. Am. J. Clin. Nutr. 72, 844-852 (2000).
59. Chester EA. Soy for cardiovascular indications. Am. J. Health Syst. Pharm. 58(8), 663-666 (2001).
60. Teede HJ, Dalais FS, Kotsopoulos D et al. Dietary soy has both beneficial and potentially adverse cardiovascular effects: a placebo-controlled study in men and post-menopausal women. J. Clin. Endocrinol. Metab. 86, 3053 (2001).
61. Ahonen MH, Tenkanen L, Teppo L et al. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control. 11, 847 (2000).
62. Tuohimaa P, Tenkanen L, Ahonen M et al. Both high and low levels of blood vitamin D axe associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. Int. J. Cancer 108(1), 104-108 (2004).
63. Kristal AR, Cohen JH, Qu P et al. Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 719-725 (2002).
64. Corder EH, Guess HA, Hulka BS et al. Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol. Biomarkers Prev. 2, 467 (1993).
65. Gann PH, Ma J, Hennekens CH, Hollis BW, Haddad JG, Stampfer MJ. Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 5(2), 121-126 (1996).
66. Nomura AM, Stemmermann GN, Lee J et al. Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control 9(4), 425-432 (1998).
67. Platz EA, Michael F, Leitzmann MF et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15, 255-265 (2004).
68. Jacobs ET, Giuliano AR, Martínez ME, Hollis BW, Reid ME, Marshall JR. Plasma levels of 25-hydroxyvitamin D, 1,25 dihydroxyvitamin D and the risk of prostate cancer. J. Steroid Biochem. Mol. Biol. 89-90(1-5), 533-537 (2004).
69. Jain MG, Hislop GT, Howe GR, Burch JD, Ghadirian P. Alcohol and other beverage use and prostate cancer risk among Canadian men. Int. J. Cancer 78(6), 707-711 (1998).
70. Jian L, Xie LP, Lee AH, Binns CW. Protective effect of green tea against prostate cancer: a case-control study in southeast China. Int. J. Cancer 108(1), 130-135 (2004).
71. Bettuzzi S, Brausi M, Fizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res. 66(2), 1234-1240 (2006).
72. Ellison LF. Tea and ocher beverage consumption and prostate cancer risk: a Canadian retrospective cohort study. Eur. J. Cancer Prev. 9(2), 125-130 (2000).
73. Slattery ML, West DW. Smoking, alcohol, coffee, tea, caffeine, and theobromine: risk of prostate cancer in Utah (United States). Cancer Causes Control. 4(6), 559-563 (1993).